Prosecution Insights
Last updated: May 29, 2026
Application No. 18/654,220

METHODS SUITABLE FOR DISRUPTING A BIOFILM, AND/OR KILLING BACTERIA CONTAINED IN A BIOFILM

Final Rejection §DOUBLEPATENT
Filed
May 03, 2024
Priority
Aug 13, 2020 — provisional 63/065,069 +1 more
Examiner
ROZOF, TIMOTHY R
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kenvue Brands LLC
OA Round
2 (Final)
73%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
97%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
693 granted / 955 resolved
+12.6% vs TC avg
Strong +24% interview lift
Without
With
+24.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
40 currently pending
Career history
989
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
23.9%
-16.1% vs TC avg
§102
28.4%
-11.6% vs TC avg
§112
21.4%
-18.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 955 resolved cases

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION This is a response to Applicant’s communication filed October 21, 2025. Application No. 18/654,220, filed May 3, 2024, is a Continuation of U.S. Nonprovisional application No. 17/400,733, filed August 12, 2021 (issued U.S. Patent No. 12,005,038) which claims the benefit of U.S. Provisional application No. 63/065,069, filed August 13, 2020. In a preliminary amendment filed May 3, 2024, Applicant cancelled claims 1-20 and added new claims 21-40. Claims 21-40 are pending. Rejections Withdrawn The rejection of claim 34 and 36-40 under 35 U.S.C. 102(a)(1) as being anticipated by Sengupta et al., U.S. Patent No. 10,071,103, in view of Applicant’s October 21, 2025, Amendment & Remarks. The rejection of claims 21-40 under 35 U.S.C. 103(a) as being unpatentable over Sengupta et al., US 10,071,103 B2, in view of Kantikosum et al., 12 Clin Cosmet Investig Dermatol. 151-161 (2019) (cited on the July 24, 2024, IDS); Garofalo et al., 12 Clin Cosmet Investig Dermatol. 363-369 (May 6, 2019) (cited on the July 24, 2024, IDS); and Chen et al., US 2020/0030202 A1, is withdrawn in view of Applicant’s October 21, 2025, Amendment & Remarks. Rejections Maintained Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. The rejection of claims 21-40 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim1-20 of U.S. Patent No. 11,890,263; claims 1-10 of U.S. Patent No. 11,986,447; claims 1-8 of U.S. Patent No. 12,005,038 (the patented parent application); claims 21-40 of copending Application No. 18/411,391 (reference application); and claims 21-38 and 40-42 of copending Application No. 18/640,883. Applicant requested that these rejections be held in abeyance until allowable subject matter is found. Other than these nonstatutory double patenting rejections the claims are otherwise allowable. It is suggested that Applicant file a Terminal Disclaimer(s) to obviate these rejections. Conclusion No claim is allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached Monday - Friday, 9:00 a.m. -5:00 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached on (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIMOTHY R ROZOF/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

May 03, 2024
Application Filed
May 21, 2025
Non-Final Rejection mailed — §DOUBLEPATENT
Oct 21, 2025
Response Filed
Dec 31, 2025
Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636277
METHODS FOR TREATING DEVELOPMENTAL DYSPLASIS OF HIP
1y 0m to grant Granted May 26, 2026
Patent 12630532
Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer
2y 5m to grant Granted May 19, 2026
Patent 12622899
METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS WITH DEUPIRFENIDONE
9m to grant Granted May 12, 2026
Patent 12616687
TREATMENT OF VIRAL INFECTION, DISEASE OR DISORDER USING A SELECTIVE S1R AGONIST
3y 6m to grant Granted May 05, 2026
Patent 12612365
COMPOUNDS AND METHODS FOR TREATING ALCOHOL DISORDER
4y 5m to grant Granted Apr 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
73%
Grant Probability
97%
With Interview (+24.0%)
2y 0m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 955 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month